Protocol Reference — ARA-290

Standard Protocol

4 mg SC once daily for 28 days

Phase IIb optimal dose. Balances nerve regeneration signal with high tolerability.

Experimental Weight-Based

30-60 mcg/kg SC once daily or twice daily (BID)

Preclinical models for acute injury (stroke, renal) used weight-based dosing with more frequent administration.

Cycle Length

28 days on, then observation period

The Phase II trial design. No data exists on optimal rest period between cycles.

Time to Effect

Nerve regeneration measurable at 28 days; metabolic effects persist to Day 56

Structural nerve changes require the full cycle. Metabolic improvements (HbA1c, lipids) continue 28 days beyond the final dose.

Half-Life Context

~20 minutes subcutaneous

Very short. Despite this, daily dosing produced structural nerve regrowth, suggesting the signalling cascade initiated by IRR activation outlasts the peptide's plasma presence.